ArticleInternational cancer conference journal2025
A case of autoimmune hemolytic anemia with cold agglutinin disease post-operation for recurrent ovarian cancer.
Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hemolytic anemia is a rare complication following surgery for recurrent ovarian cancer, with no previously reported cases of postoperative cold agglutinin disease. This report presents a 47-year-old woman who developed cold agglutinin disease after surgery for recurrent ovarian cancer. On postoperative day 7, she experienced severe anemia, renal dysfunction, and elevated bilirubin levels. Hemolysis was initially suspected owing to blood sampling and bleeding; however, autoimmune hemolytic anemia was diagnosed on postoperative day 8 with a positive Coombs test. Despite treatment with steroids, blood transfusions, and hemodialysis, the patient's condition remained unchanged. Cold agglutinin disease was confirmed on postoperative day 10 with a cold agglutinin titer of 512. Heated blood transfusions, along with rituximab and sutimlimab, led to clinical improvement. The patient was discharged on postoperative day 54 and continued on maintenance therapy. Stress from invasive surgery may activate the complement system, triggering cold agglutinin disease. Early diagnosis and treatment are crucial for preventing severe complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.